Johnson & Johnson Acquires Alios BioPharma for $1.75 Billion
Johnson & Johnson announced the acquisition of Alios BioPharma to expand their portfolio of therapeutics for viral infections.
Johnson & Johnson announced on Sept. 30, 2014 that they have reached an agreement to acquire Alios BioPharma, a clinical-stage biopharmaceutical company that develops therapies for viral diseases, with a specialization in viral respiratory disease therapies. The $1.75 billion acquisition of Alios includes the compound AL-8176, an oral, anti-respiratory syncytial virus (RSV) nucleoside analog currently in Phase IIa studies.
“We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy,” said William N. Hait, MD, PhD, global head, research & development, Janssen Pharmaceutical Companies of Johnson & Johnson. “AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.”
Sources:
Johnson & JohnsonAlios BioPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
